محتوى طبي

Transplant-Associated Ehrlichia ewingii Infection in Pediatric Liver Recipient, United States, 2023

Transplant-Associated Ehrlichia ewingii Infection in Pediatric Liver Recipient, United States, 2023

AAdmin
١٩ نوفمبر ٢٠٢٦
3 دقيقة قراءة
Transplant-Associated Ehrlichia ewingii Infection in Pediatric Liver Recipient, United States, 2023

A-Z Index × Submit A-Z Index × Submit A-Z Index Search Dropdown × Submit Facebook Twitter LinkedIn Syndicate Emerging Infectious Disease journal ISSN: 1080-6059 Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Cite This Article Open modal Citation for Media

We report a case investigation of a pediatric patient in the United States who experienced fever, nausea, dyspnea, and pancytopenia 18 days after a liver transplant. Diagnostic testing and public health investigation confirmed a donor-derived Ehrlichia ewingii infection. This case highlights rare tickborne pathogens as a cause of donor-derived infections and the consideration for extended antimicrobial therapy.

Ehrlichiosis is characterized by influenza-like symptoms such as fever, headache, nausea, and muscle aches. In the United States, ehrlichiosis can be caused by infections from 3 pathogenic tickborne bacterial species, Ehrlichia chaffeensis , Ehrlichia ewingii , and Ehrlichia muris subsp. eauclairensis . The epidemiology of E. chaffeensis and E. ewingii is associated with the distribution of the lone star tick ( Amblyomma americanum ), which occurs primarily in the northeastern, southern, and midwestern United States. E. muris subsp. eauclairensis infections are isolated to Wisconsin and Minnesota and transmitted by the blacklegged tick ( Ixodes scapularis ) ( 1 ).

During 2008–2022, a total of 327 cases of E. ewingii infection from 28 states were reported to the Centers for Disease Control and Prevention (CDC), compared with 19,918 cases of E. chaffeensis infections from 47 states ( 2 , 3 ). E. ewingii infections are likely underreported because diagnosis relies on serologic assays that cannot differentiate among Ehrlichia species. The nonspecific clinical signs and symptoms of ehrlichiosis and gaps in healthcare provider knowledge contribute to underdiagnosis and underreporting ( 2 ). Ehrlichiosis is uncommon among transplant recipients, and donor-derived infections are exceedingly rare ( 4 ). Here, we report on a case of E. ewingii infection in a pediatric liver recipient.

In the fall of 2023, a child 10–15 years of age with end-stage liver disease secondary to primary sclerosing cholangitis underwent deceased donor liver transplantation. The child had no travel outside the state in which the transplant was performed within the 10 weeks before the surgery and had no outdoor or animal exposures and no known tick bites. The child permanently resided outside the United States, in an area where ehrlichiosis has not been reported.

Transplant surgery was uncomplicated and required only autologous cell saver transfusion. At transplantation, serologic testing revealed IgG to Epstein-Barr virus and cytomegalovirus in both the donor and recipient. The liver recipient received intravenous (IV) methylprednisolone (500 mg, followed by 50 mg every 12 h with taper), mycophenolate mofetil (883 mg IV every 12 h, transitioned to 1,000 mg oral every 12 h), and oral tacrolimus (3 mg every 12 h), as part of standard immunosuppressive therapy. Ten days after transplantation, a biopsy revealed mild acute cellular rejection in the patient. The patient was treated with IV methylprednisolone (1,000 mg every other day for 3 doses). Asymptomatic cytomegalovirus viremia developed in the patient 12 days after transplantation and resolved with oral valganciclovir (900 mg every…